TrialAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2010

Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.

Melanie S Joy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.